



- (51) International Patent Classification:
C07D 403/00 (2006.01) *C07D 213/55* (2006.01)
- (21) International Application Number:
PCT/US2017/061875
- (22) International Filing Date:
15 November 2017 (15.11.2017)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
62/423,126 16 November 2016 (16.11.2016) US
- (71) Applicant: **ABIDE THERAPEUTICS, INC.** [US/US];
10835 Road to the Cure, Suite 250, San Diego, California
92121 (US).
- (72) Inventors: **GRICE, Cheryl A.**; 924 Springwood Lane,
Encinitas, California 92024 (US). **JONES, Todd K.**; 546
Marview Drive, Solana Beach, California 92075 (US).
GRIMM, Kurt G.; 2658 Del Mar Heights Road, #249,
Del Mar, California 92014 (US). **BLANKMAN, Jacqueline
Lorayne**; 11215 Lianres Street, San Diego, California
92129 (US). **BEALS, Channing Rodney**; 4100 Twilight
Ridge, San Diego, California 92130 (US).
- (74) Agent: **HOSTETLER, Michael J.**; WILSON SONSINI
GOODRICH & ROSATI, 650 Page Mill Road, Palo Alto,
California 94304 (US).
- (81) Designated States (*unless otherwise indicated, for every
kind of national protection available*): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,

DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN,
HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP,
KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME,
MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ,
OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA,
SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN,
TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

- (84) Designated States (*unless otherwise indicated, for every
kind of regional protection available*): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:


- *as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))*
- *as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))*

Published:

- *with international search report (Art. 21(3))*

(54) Title: CRYSTALLINE FORMS OF A MAGL INHIBITOR

FIGURE 1



(57) Abstract: Described herein is the MAGL inhibitor 1,1,1,3,3,3-hexafluoropropan-2-yl 4-(2-(pyrrolidin-1-yl)-4-(trifluoromethyl)benzyl)piperazine-1-carboxylate, including crystalline forms and pharmaceutically acceptable salts and solvates thereof.